SETBP1 is dispensable for normal and malignant hematopoiesis

Area of Science:

• Molecular Biology
• Cancer Biology
• Epigenetics

Background:

• SETBP1 mutations are found in myeloid malignancies, suggesting a role in cancer.
• Mutant SETBP1 is thought to amplify wild-type SETBP1 functions, leading to hematopoietic cell transformation.
• The role of endogenous SETBP1 in normal and malignant hematopoiesis remains unclear.

Purpose of the Study:

• To investigate the function of endogenous SETBP1 in normal and malignant hematopoiesis.
• To determine if SETBP1 is essential for acute myeloid leukemia (AML) development or maintenance.
• To explore the implications of SETBP1's role in protein degradation pathways.

Main Methods:

• Analysis of primary AML and healthy samples.
• Studies on cancer cell lines.
• Generation and analysis of a novel murine model (Vav1-iCre;Setbp1^fl/fl).

Main Results:

• SETBP1 depletion minimally impacts normal hematopoiesis, including stem cell self-renewal and differentiation.
• SETBP1 loss does not significantly alter transcription or chromatin accessibility in normal cells.
• Despite high SETBP1 mRNA correlating with poor prognosis in AML, SETBP1 is dispensable for AML development and maintenance.
• AML does not show dependency on SETBP1 mRNA expression, contrary to expectations.

Conclusions:

• Endogenous SETBP1 is not essential for normal hematopoiesis.
• SETBP1 is dispensable for AML development and maintenance, despite its association with poor prognosis.
• A physiologically nonessential gene can function as an oncogene when protein degradation machinery is compromised.